Lightnews — Scholar-powered news

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 27

@sinaiimmuno.bsky.social

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 27

www.mountsinai.org/about/newsro...
@sinaiimmuno.bsky.social

Mount Sinai Scientists Identify Three Potent Human Antibodies Against Mpox, Paving the Way for New Protective Therapies

www.mountsinai.org

1 3

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 27

Check our new paper here!
👇🏼

Cell - a Cell Press journal @cp-cell.bsky.social · Aug 27

Now online! Human monoclonal antibodies targeting A35 protect from death caused by mpox

Human monoclonal antibodies targeting A35 protect from death caused by mpox

Three potent mAbs against the conserved MPXV A35 protein block viral spread, protect against lethal infection in mice, and align with protective antibody responses in convalescent humans, establishing A35 as a key target for next-generation orthopoxvirus therapies.

dlvr.it

3

Reposted by Camila Coelho, PhD MBA

Science X / Phys.org @sciencex.bsky.social · Aug 26

Three monoclonal antibodies targeting the mpox virus protein A35 have shown strong protection against severe disease in laboratory and animal models, indicating potential for new therapeutic approaches. doi.org/g9zg4h

Three potent human antibodies against mpox pave way for new protective therapies

A team from the Microbiology Department at the Icahn School of Medicine at Mount Sinai has discovered three powerful monoclonal antibodies from a person who had previously been infected with mpox (formerly known as monkeypox).

medicalxpress.com

3 2

Reposted by Camila Coelho, PhD MBA

Waggoner Lab @labwaggoner.bsky.social · Aug 27

1 2

Reposted by Camila Coelho, PhD MBA

Waggoner Lab @labwaggoner.bsky.social · Aug 27

Human monoclonal antibodies targeting A35 protect from death caused by monkeypox virus @cellcellpress.bsky.social @carolilucas.bsky.social @vivianasimonlab.bsky.social @mschotsaert.bsky.social
www.cell.com/cell/fulltex...

1 5 7

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 27

It starts in 10 minutes!
Link below👇
isv-online.org/event/isv-au...

Speeding up vaccine design and antibody discovery using cryoEM and AI/ML

Title:Speeding up vaccine design and antibody discovery using cryoEM and AI/ML Speaker: Andrew Ward, Scripps Research, United States MODERATOR: Camila Coelho, Icahn School of Medicine at Mou...

isv-online.org

2

Reposted by Camila Coelho, PhD MBA

Quintana Lab @juanquintana.bsky.social · Aug 27

Exciting data from @camilahcoelho.bsky.social lab! Congratulations to the team!

Waggoner Lab @labwaggoner.bsky.social · Aug 27

Human monoclonal antibodies targeting A35 protect from death caused by monkeypox virus @cellcellpress.bsky.social @carolilucas.bsky.social @vivianasimonlab.bsky.social @mschotsaert.bsky.social
www.cell.com/cell/fulltex...

1 6

Reposted by Camila Coelho, PhD MBA

Goran Bajic @gogo-science.bsky.social · Aug 26

New paper from the Coelho lab with a modest contribution from us:

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

🚨 New article! Our study "Human monoclonal antibodies protect against death caused by mpox" is now published:
👉 www.cell.com/cell/fulltex...
[1/9]

Human monoclonal antibodies targeting A35 protect from death caused by mpox

Three potent mAbs against the conserved MPXV A35 protein block viral spread, protect against lethal infection in mice, and align with protective antibody responses in convalescent humans, establishing...

www.cell.com

1 3

Reposted by Camila Coelho, PhD MBA

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 23

Join us next Wednesday as we hear from the great work from the Ward lab!

International Society for Vaccines News @isv-news.bsky.social · Aug 12

ISV August Webinar: mark your calendars today! isv-online.org/event/isv-au...

ISV August Webinar

Title: TBC Speaker: Andrew Ward, Scripps Research, United States Time Zones: America & Europe: 08:00 (PDT) |11:00 (EDT) | 16:00 (BST) | 17:00 (CEST) Central & South America: 09:00 (Mexic...

isv-online.org

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

🙌 This work was a major collaboration with incredible colleagues across the US, and we’re grateful for Mount Sinai's support.
#Mpox #Antibodies #Immunology
[9/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

💡 Translational highlight: In mpox patients, polyclonal antibodies targeting this same A35 groove were enriched and correlated with better outcomes (shorter symptoms, no hospitalization).
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

Structural studies revealed all these mAbs, despite very different binding loops, converge on the groove formed by the A35 dimer.
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

How do they work?
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

Treatment worked at just ~5 mg/kg...that’s 10x lower than the antibody doses used during recent Ebola outbreaks.
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]

1 1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

✨ In collaboration with Ian Wilson, Bernie Moss, @carolilucas.bsky.social, @mschotsaert.bsky.social @vivianasimonlab.bsky.social, that’s exactly what we did!
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]

1 1 1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

This led us to hypothesize: if we could map where strong anti-A35 antibodies bind (the epitope), we could uncover urgently needed therapeutics and reveal viral weak spots that vaccines could target.
[3/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

💡 In 2023, our lab showed (PMID: 37475115) that people infected with mpox had unusually high antibody levels against A35, a surface protein of MPXV.
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]

1

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 26

🚨 New article! Our study "Human monoclonal antibodies protect against death caused by mpox" is now published:
👉 www.cell.com/cell/fulltex...
[1/9]

Human monoclonal antibodies targeting A35 protect from death caused by mpox

Three potent mAbs against the conserved MPXV A35 protein block viral spread, protect against lethal infection in mice, and align with protective antibody responses in convalescent humans, establishing...

www.cell.com

1 3 10

Camila Coelho, PhD MBA @camilahcoelho.bsky.social · Aug 23

Join us next Wednesday as we hear from the great work from the Ward lab!

International Society for Vaccines News @isv-news.bsky.social · Aug 12

ISV August Webinar: mark your calendars today! isv-online.org/event/isv-au...

ISV August Webinar

Title: TBC Speaker: Andrew Ward, Scripps Research, United States Time Zones: America & Europe: 08:00 (PDT) |11:00 (EDT) | 16:00 (BST) | 17:00 (CEST) Central & South America: 09:00 (Mexic...

isv-online.org

1

Reposted by Camila Coelho, PhD MBA

Line Brugière @linebrugiere.bsky.social · Aug 22

Such a great time at the #IUIS2025! Inspiring conferences by amazing scientists such as @belkaidlab.bsky.social @virusesimmunity.bsky.social @linterman.bsky.social. Also loved seeing rising stars like @camilahcoelho.bsky.social @marionbrunck.bsky.social. Thanks to James Allison for his lecture !! ❤️

2 3 8

Reposted by Camila Coelho, PhD MBA

La Jolla Institute for Immunology (LJI) @lji.org · Aug 12

Congratulations to former LJI trainee Dr. Camila Coelho (now at the Icahn School of Medicine at Mount Sinai)! 🎉

Dr. Coelho has been named a "Rising Star" by Union of Immunological Societies — an award for early-stage researchers who are revolutionizing the field! bit.ly/4mGyF3H #health #medicine

Camila Coelho, PhD, MBA, Named Rising Star by Union of Immunological Societies

bit.ly

2 4